Hong Kong stock concept tracking | National Medical Products Administration accelerates the approval of clinical pharmaceuticals, institutions bullish on the high-speed development and profit period of innovative drugs (with concept stocks)
National Medical Products Administration: Accelerate the evaluation and approval of clinically urgent products and include eligible products in the priority evaluation and approval process.
BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk
Overnight news: European and American stock indexes closed up, gold hit a new high, the European Central Bank announced a rate cut, OpenAI's large-scale reasoning model made its debut, Samsung Electronics plans large-scale layoffs globally.
For more global financial news, please go to the 24/7 real-time financial news market closing: US stocks closed higher, led by technology stocks. The Nasdaq and S&P 500 indexes have risen for the fourth consecutive day. Top 20 US stock turnover on September 12: Wells Fargo & Co. restricted from conducting new business. China concept stocks had mixed performance on Thursday, with pdd holdings up 2.2% and Beigene down 7.1%. Crude oil closed up 2.5% on Thursday as hurricane disruptions supported oil prices. Spot gold hit a new record high, while major European stock indices rose collectively. The Euro Stoxx 50 index rose 1.04%. Macro Harris urged Trump to continue the presidential debate. Trump said he would not debate with Harris anymore.
Top Gap Ups and Downs on Thursday: SNY, DEO, GOLD and More
New Additions to Roth MKM's ADR Portfolio for September
Oxford Industries Reports Weak Results, Joins Viper Energy And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Beigene's stock price was hit by bearish news! It is accused of stealing trade secrets. The company denies the accusations and vows to vigorously defend itself.
①AbbVie has once again filed a lawsuit against Beigene, accusing Beigene of stealing core business secrets to develop BTK degraders. ②Previously, AbbVie sued Beigene for patent infringement of zanubrutinib (BTK inhibitor), and the case is under review. Beigene stated that this has not had a negative impact on the research and sales of zanubrutinib in the United States.
Beigene issued 1.036 million shares under the employee stock purchase plan.
Beigene (06160) announced that on September 11, 2024, 1.036 million shares were issued in accordance with the revised and restated 2018 Employee Stock Ownership Plan, Fourth Edition.
Top Gap Ups and Downs on Wednesday: NVS, HUM, WIT and More
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
BeiGene Ltd. Employees Buy Shares Under Company Plan
Beigene (06160): According to the 2018 employee stock purchase plan, a total of 0.0797 million shares of American depositary shares were purchased.
Beigene (06160) announced that the subscription...
Top oncology conference is coming! Multiple popular anti-cancer drugs will debut, involving these A-share companies.
①The annual meeting of the European Society for Medical Oncology will be held in Barcelona, Spain in 2024; ②At the meeting, Beigene, Jiangsu Hengrui Pharmaceuticals and other listed companies will release the latest data on their oncology drugs; ③In addition, the conference will also discuss cutting-edge topics such as the impact of artificial intelligence on the diagnosis and treatment of tumors.
Abnormal movement hits directly | Stocks of innovative drugs concept are on the rise, the 2024 ESMO conference is about to be held, and institutions suggest seizing the Q3 fundamentals turning point and industry catalysis.
Innovative drug concept stocks have risen, as of press time, Beigene (06160) rose 6.97%, to HKD 124.3; Innocare-B (02162) rose 4.92%, to HKD 37.35; Innocare (09969) rose 4.91%, to HKD 5.55.
HK stocks surged, Beigene rose more than 7% after declaring clinical trial for Class 1 innovative cancer drugs.
On September 11th, Beigene (06160) rose more than 7%, as of press time, up 7.66%, at HKD 125.1, with a turnover of HKD 0.207 billion.
Are Investors Undervaluing BeiGene, Ltd. (NASDAQ:BGNE) By 28%?
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Maintains Target Price $198
Hold Rating on BeiGene Amid Mixed Sales Performance and Competitive Pressures
Express News | Beigene Announces Updates to Commercial Leadership Team